NCT05303402 - A Phase IIb/III Clinical Trial to Assess Safety and Immunogenicity of a COVID-19 Vaccine Booster Dose in Immunosupressed Adults. | Biotech Hunter

Enrollment

241

Participants

Timeline

Start Date

May 12, 2022

Primary Completion Date

July 29, 2023

Study Completion Date

December 1, 2023

Conditions

SARS CoV 2 Infection

Interventions

BIOLOGICAL

PHH-1V

COVID-19 Vaccine HIPRA, 40 mcg/dose

Trial Locations (6)

Hospital Josep Trueta, Girona

Koc University Hospital, Istanbul

Hospital Germans Trias i Pujol, Badalona

Hospital Clínic de Barcelona, Barcelona

Hacettepe University Medical Faculty Hospitals, Ankara

Ankara University Medical Faculty Hospitals, Ankara